Cell penetrating peptides as a therapeutic strategy in chronic lymphocytic leukemia

Area of Science:

• Biochemistry
• Immunology
• Oncology

Background:

• Protein phosphatase 2A (PP2A) is crucial for physiological and developmental processes.
• Dysregulation of PP2A is implicated in various diseases, including cancer.
• Targeting specific protein interactions offers a precise therapeutic approach.

Purpose of the Study:

• To investigate the therapeutic potential of a peptide blocking the caspase-9/PP2A interaction.
• To assess the tumor-specific apoptotic effects of the DPT-C9h peptide in chronic lymphocytic leukemia (CLL).
• To evaluate the safety of DPT-C9h on non-tumor cells.

Main Methods:

• Isolation of primary tumor B cells from CLL patients and B cells from healthy donors.
• Treatment of isolated cells with the DPT-C9h peptide.
• Assessment of apoptosis induction in B cells, T cells, NK cells, and monocytes.

Main Results:

• The DPT-C9h peptide selectively induced apoptosis in primary tumor B cells from CLL patients.
• B cells from healthy donors, as well as T cells, NK cells, and monocytes from both CLL patients and healthy donors, were not affected.
• The peptide demonstrated significant tumor specificity.

Conclusions:

• The caspase-9/PP2A interaction is a viable target for CLL therapy.
• The DPT-C9h peptide exhibits promising tumor-specific apoptotic activity against CLL B cells.
• This peptide represents a novel therapeutic strategy for treating chronic lymphocytic leukemia.